Menkes Disease
0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Sentynl TherapeuticsCA - Solana Beach
2 programsLong Term Follow-UpN/A1 trial
copper histidinateN/A1 trial
Active Trials
NCT04074512Approved For Marketing
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Sentynl TherapeuticsLong Term Follow-Up
Clinical Trials (2)
Total enrollment: 50 patients across 2 trials
Copper Histidinate Treatment for Menkes Disease
N/AApproved For Marketing
Long Term Follow-up on Menkes Disease Patients
Start: Dec 2019Est. completion: Aug 202650 patients
N/AActive Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space